← Leaderboards
Parambir Singh Dulai
Northwestern University
$5,769,384
Attributed
$10,592,908
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,592,908 · 5
By mechanism
U01$7,269,328 · 1
R01$2,351,221 · 2
U19$625,858 · 1
U34$346,501 · 1
Top collaborators
- Lauren Balmert Bonner4 shared
- Ronen Sumagin3 shared
Most similar at Northwestern University
Same institution · by research overlap
- Richard G Wunderink$10,706,481
- Lauren Balmert Bonner$4,445,085
- Benjamin David Singer$9,234,980
- Howard Lee Lipton$10,378,698
- Allen Glicksman$388,269
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsMediatingInflammationTranscriptomicsTreatment ResponseMucous MembraneNeutrophilEpitheliumDouble-Blind MethodInjuryUlcerative ColitisResponseFunctional DisorderDigitalMessenger RnaTreatment EfficacyCostCohortImmuneSteroidsChronicBiological ProductsClinical RemissionResolution
Grant awards (11)
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial$2,464,155
U01 · FY2025 · DK · contact PI
Identifying Neutrophil Specific Mechanisms for Resistance to Biologics in Ulcerative Colitis$677,602
R01 · FY2025 · DK
Selenium Supplementation for Moderate-Severe Ulcerative Colitis Flares$320,000
R01 · FY2025 · DK · contact PI
Technology Core$288,358
U19 · FY2025 · AI · contact PI
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial$2,365,589
U01 · FY2024 · DK · contact PI
Identifying Neutrophil Specific Mechanisms for Resistance to Biologics in Ulcerative Colitis$655,523
R01 · FY2024 · DK
Technology Core$337,500
U19 · FY2024 · AI · contact PI
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Phase 3 Multi-Center, Randomized, Double-Blind, Sham-Controlled Trial$2,439,584
U01 · FY2023 · DK · contact PI
Identifying Neutrophil Specific Mechanisms for Resistance to Biologics in Ulcerative Colitis$698,096
R01 · FY2023 · DK
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares: A Multi-Center, Randomized, Double-Blind, Sham Controlled Trial (HBOT-UC)$346,500
U34 · FY2021 · DK · contact PI
Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Moderate to Severe Flares$1
U34 · FY2021 · DK · contact PI